Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 144, Issue 5, Pages 686-703
Publisher
Oxford University Press (OUP)
Online
2015-10-21
DOI
10.1309/ajcpt41tcbuevdqc
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer
- (2013) Aaron S. Mansfield et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Analysis ofHER2status in breast carcinoma by fully automatedHER2fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH
- (2013) Nara Yoon et al. APMIS
- SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
- (2013) Jocelyne Jacquemier et al. BMC CANCER
- Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
- (2013) Zsuzsanna Varga et al. BMC CANCER
- HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
- (2013) Ji-Won Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens
- (2013) Daniela Furrer et al. Diagnostic Pathology
- Instant-quality fluorescencein-situhybridization as a new tool forHER2testing in breast cancer: a comparative study
- (2013) Camille Franchet et al. HISTOPATHOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
- (2013) Wedad M Hanna et al. MODERN PATHOLOGY
- HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
- (2013) Diana P. English et al. Molecular Diagnosis & Therapy
- Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues
- (2013) Anna Sapino et al. Frontiers in Oncology
- Evaluation of Reliability of FISH Versus Brightfield Dual-probe In Situ Hybridization (BDISH) for Frontline Assessment of HER2 Status in Breast Cancer Samples in a Community Setting
- (2012) Beatriz N. Schiavon et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
- (2012) Michael Bilous et al. BREAST CANCER RESEARCH AND TREATMENT
- mRNA In Situ Hybridization (HistoSonda)
- (2012) Laia Bernet et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections
- (2012) Hiroaki Nitta et al. Diagnostic Pathology
- Silver-EnhancedIn SituHybridization as an Alternative to FluorescenceIn SituHybridization for Assaying HER2 Amplification in Clinical Breast Cancer
- (2012) Kyeongmee Park et al. Journal of Breast Cancer
- The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor and HER2 expression in invasive breast carcinoma
- (2012) Isil Z Yildiz-Aktas et al. MODERN PATHOLOGY
- Chromogenicin situhybridization (CISH) to detectHER2gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescencein situhybridization (FISH)
- (2012) Shinichiro Kiyose et al. PATHOLOGY INTERNATIONAL
- Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences
- (2012) Steen H. Matthiesen et al. PLoS One
- Evaluation of Dual Immunohistochemistry and Chromogenic In Situ Hybridization for HER2 on a Single Section
- (2011) Emily S. Reisenbichler et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains
- (2011) Anja Brügmann et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
- (2011) J Lehmann-Che et al. BRITISH JOURNAL OF CANCER
- Current technologies for HER2 testing in breast cancer
- (2011) C.B. Moelans et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing
- (2011) Cheng-Cheng Hwang et al. HISTOPATHOLOGY
- Serum HER2 levels determined by two methods in patients with metastatic breast cancer
- (2011) Naoki Hayashi et al. International Journal of Clinical Oncology
- High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients
- (2011) Yanan Kong et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Quantitative Reverse Transcriptase Polymerase Chain Reaction and the Oncotype DX Test for Assessment of Human Epidermal Growth Factor Receptor 2 Status: Time to Reflect Again?
- (2011) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
- (2011) David J. Dabbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups
- (2011) Motohiko Kato et al. JOURNAL OF GASTROENTEROLOGY
- Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
- (2011) David G. Hicks et al. Labmedicine
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Testing HER2 in Breast Cancer
- (2011) Anja Brügmann et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A UK NEQAS ISH Multicenter Ring Study Using the VentanaHER2Dual-Color ISH Assay
- (2010) J.M.S. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Determination of the Her-2/neu Gene Amplification Status in Cytologic Breast Cancer Specimens Using Automated Silver-enhanced In-situ Hybridization (SISH)
- (2010) Florian Rudolf Fritzsche et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma
- (2010) Bettina G. Papouchado et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
- (2010) A. Noske et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
- (2010) Semir Vranic et al. CANCER
- Determination ofHER2amplification in primary breast cancer using dual-colour chromogenicin situhybridization is comparable to fluorescencein situhybridization: a European multicentre study involving 168 specimens
- (2010) Tomás García-Caballero et al. HISTOPATHOLOGY
- Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
- (2010) Frederick L. Baehner et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromogenic In Situ Hybridization
- (2009) J.M.S. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Emerging Technologies for Assessing HER2 Amplification
- (2009) Frédérique Penault-Llorca et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
- (2009) Cathy B. Moelans et al. BREAST CANCER RESEARCH AND TREATMENT
- Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
- (2009) Patricia Diana Sørensen et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays
- (2009) Glenn D. Francis et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer
- (2009) Marianne Pedersen et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens
- (2009) Tommaso Susini et al. GYNECOLOGIC ONCOLOGY
- Evaluation of automated silver-enhancedin situhybridization (SISH) for detection ofHER2gene amplification in breast carcinoma excision and core biopsy specimens
- (2009) S Shousha et al. HISTOPATHOLOGY
- Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
- (2009) Siân Lennon et al. JOURNAL OF CLINICAL ONCOLOGY
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis
- (2009) Caterina Marchiò et al. JOURNAL OF PATHOLOGY
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues
- (2009) Sylvia Streit et al. Nature Protocols
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer
- (2009) Francisco J. Esteva et al. Nature Reviews Clinical Oncology
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry
- (2009) Anikó Kovács et al. PATHOLOGY RESEARCH AND PRACTICE
- HER2+ Breast Cancer
- (2008) David G. Hicks et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
- (2008) V. Ludovini et al. ANNALS OF ONCOLOGY
- Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
- (2008) Vivien H. C. Bramwell et al. BREAST CANCER RESEARCH AND TREATMENT
- Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
- (2008) Suhail M. Ali et al. CANCER
- Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and Immunohistochemistry
- (2008) Elisa Capizzi et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
- (2008) Hiroaki Nitta et al. Diagnostic Pathology
- Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
- (2008) Isabelle Vanden Bempt et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation